With this agreement, Eisai will assume exclusive rights for development and marketing of these products in Japan and in the Euro-Asia countries and region where the products are yet to be sold. For China and the Euro-Asia countries and region where the products are currently sold, Eisai will assume exclusive first negotiation rights, with exclusive marketing rights in China upon termination of the existing agreement between Minophagen Pharmaceutical and its current local marketing partner.
The companies expect to transfer the marketing activities to Eisai in China on April 1, 2009. In Japan, transfer of the marketing activities for stronger Neo-Minophagen C and Glycyron tablets are expected to take place on April 1, 2008 and October 1, 2008, respectively.
With this agreement, Eisai is expected to enhance its product lineup for the gastrointestinal disorders area that is available in countries in Asia including Japan and China, and thereby make further contributions to increase the benefits to patients and their families.